Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

David A. Smith; Carlota Fernandez-Antunez; Andrea Magri; Rory Bowden; Nimisha Chaturvedi; Jacques Fellay; John McLauchlan; Graham R. Foster; William L. Irving; STOP-HCV Consortium; Peter Simmonds; Vincent Pedergnana; Santseharay Ramirez; Jens Bukh; Eleanor Barnes; M. Azim Ansari

doi:10.1038/s41467-021-25649-6

Nature Communications (Oct 2021)

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

David A. Smith,
Carlota Fernandez-Antunez,
Andrea Magri,
Rory Bowden,
Nimisha Chaturvedi,
Jacques Fellay,
John McLauchlan,
Graham R. Foster,
William L. Irving,
STOP-HCV Consortium,
Peter Simmonds,
Vincent Pedergnana,
Santseharay Ramirez,
Jens Bukh,
Eleanor Barnes,
M. Azim Ansari

Affiliations

David A. Smith: Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
Carlota Fernandez-Antunez: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen
Andrea Magri: Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
Rory Bowden: Wellcome Centre for Human Genetics, University of Oxford
Nimisha Chaturvedi: School of Life Sciences, École Polytechnique Fédérale de Lausanne
Jacques Fellay: School of Life Sciences, École Polytechnique Fédérale de Lausanne
John McLauchlan: MRC-University of Glasgow Centre for Virus Research
Graham R. Foster: Barts Liver Centre, Blizard Institute, Queen Mary University of London
William L. Irving: NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham
STOP-HCV Consortium
Peter Simmonds: Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
Vincent Pedergnana: MIVEGEC, Université de Montpellier, CNRS
Santseharay Ramirez: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen
Jens Bukh: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen
Eleanor Barnes: Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
M. Azim Ansari: Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford

DOI: https://doi.org/10.1038/s41467-021-25649-6
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

Sofosbuvir is a common therapy in hepatitis C virus infection, which targets the NS5B polymerase. Here, Smith et al. analyze the association between whole genome HCV polymorphisms and sofosbuvir treatment failure and identify three common polymorphisms present in non-targeted NS2 and NS3 proteins associated with reduced treatment response.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal